About this Research Topic
The discovery process relevant to human pathobiology had been somewhat limited by the lack of suitable disease models and cell type-specific approaches for precise molecular analysis. The recent development of human patient-specific stem cell- or organoid-based disease models and single cell- or cell type-based analyses of the transcriptome, translatome and proteome allow an unprecedented opportunity for elucidating the spatiotemporal pathological sequences. These platforms now help to capture the initiating steps of disease causing mechanisms, and accelerate the discovery of novel targets for the treatment of various neurodegenerative conditions. Although further characterization and the combined use of novel human disease platforms with animal models remain necessary, this approach is opening opportunities for transforming translational science, including the development of personalized medicine.
The collection of articles in this Research Topic will represent the dynamic development of disease models that has facilitated discoveries of novel glial or other non-neuronal pathologies, advances in experimental treatments and clinical trials targeting glial and immune cell pathways in neurodegenerative diseases. The disorders we would like to mainly focus on include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer’s disease (AD), corticobasal degeneration (CBD), Parkinson’s disease (PD), progressive supranuclear palsy (PSP), Huntington’s disease (HD) and other disorders characterized by neurodegeneration, such as glaucoma. We would be interested in receiving manuscripts incorporating basic or translational Original Research, Mini-Reviews and Reviews, which aim at covering the novel and rapidly developing aspects of the field.
Keywords: translational neuroscience, Glia, Stem cells, Neurodegeneration, Human disease models
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.